Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aquestive Therapeutics reports robust 2022 performance and strategic growth plans

Aquestive Therapeutics showcased strong performance in 2022, focusing on innovation, strategic partnerships, and financial management.
While facing challenges such as generic competition and financial discipline, the company is well-positioned to capitalize on opportunities for growth and market expansion.
With a clear emphasis on advancing key products, securing collaborations, and navigating market dynamics, Aquestive is poised for continued success in 2023 and beyond.

Aquestive Therapeutics reports strong Q1 performance and eyes global expansion

Aquestive Therapeutics' Q1 performance reflects strong revenue growth, debt reduction, and strategic advancements in product development.
While facing challenges in European pricing and Chinese market visibility, the company maintains a focus on operational efficiency and market expansion.
Opportunities in FDA interactions, market access, and upcoming regulatory meetings position Aquestive for future growth and product success.
Overall, Aquestive Therapeutics demonstrates resilience and strategic planning in navigating market challenges and driving growth.

Aquestive Therapeutics reports improved Q2 performance and eyes global expansion

Aquestive Therapeutics reported a strong Q2 2023 performance with revenue growth and reduced net loss. The company faces financial challenges but holds strengths in its financial position and growth outlook. Opportunities for expansion and partnerships present avenues for future growth.

Aquestive Therapeutics reports strong Q3 performance and optimistic growth outlook

Aquestive Therapeutics showcased robust financial performance, strategic debt refinancing, and promising product developments in Q3 2023. While facing challenges in competitive intelligence and trial efficiency, the company is optimistic about future growth opportunities and remains focused on expanding its capabilities.

Aquestive reports robust Q4 earnings, eyes billion-dollar sales opportunities

Aquestive Therapeutics showcases strong financial performance in Q4 2023, with revenue growth and improved EBITDA loss, setting a positive trajectory for future growth. Strategic focus on launching Anaphylm and Libervant, along with proactive commercial preparations, underlines the company's commitment to innovation and market expansion. Despite regulatory and competitive challenges, Aquestive's confidence in FDA processes and international market exploration present promising opportunities for long-term success.

Aquestive Therapeutics reports revenue growth and plans for future launches

Aquestive Therapeutics reported revenue growth in Q3 2024 driven by successful product launches and positive study results, despite increased expenses.
The company's focus on key programs and upcoming milestones signals a commitment to innovation and addressing market needs for sustained growth.
While facing challenges in managing expenses and profitability, Aquestive's strong financial position and strategic initiatives offer opportunities for future growth and market expansion.
Overall, Aquestive's performance in Q3 2024 reflects a balance between investment in future growth and financial stability, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Asbury Automotive Group

Globalstar

Westlake Chemical Partners LP

Xometry

The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Xometry's AI-driven procurement software in a specialized B2B marketplace shows high-growth potential to Bert Hochfeld, making it a promising investment. Grassroots Trading argues that Boston Scientific's acquisition of Axonics enhances its urology offerings, positioning it strongly in the sacral neuromodulation field.

Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics +

Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q3 2024 Earnings Call Transcript November 5, 2024 8:00 AM ET Company Participants Bennett Watson - IR, ICR Westwicke IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of Sales and Marketing Carl Kraus - CMO Steve Wargacki - CSO Conference Call Participants Roanna Ruiz - Leerink Partners David Amsellem - Piper Sandler Francois Brisebois - Oppenheimer Raghuram Selvaraju - HC Wainwright & Co. Jason Butler - JMP Securities Thomas Flaten - Lake Street Capital Markets Gary Nachman - Raymond James James Molloy - Alliance Global Partners Operator Good morning, and welcome to the Aquestive Therapeutics Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.

Aquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings Call Transcript

Aquestive Therapeutics specializes in innovative film-based medicines and epinephrine products & delivery. The company's PharmFilm and Adrenaverse platforms offer unique competitive advantages, making it a strong investment opportunity. A risk-adjusted valuation indicates that Aquestive is currently undervalued compared to its market price.

Aquestive: Rare Opportunity With Dual Platform Strategy

Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.03 per share a year ago.

Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates

WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, reported financial results for the third quarter, which ended September 30, 2024, and provided an update on recent developments in its business.

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

WARREN, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today hosted a virtual investor day highlighting the Company's pipeline inclusive of Anaphylm™ (epinephrine) Sublingual Film and AQST-108 (epinephrine) Topical Gel, both product candidates emerging from the Company's Adrenaverse™ epinephrine prodrug platform. The event included presentations by members of the Aquestive management team and by distinguished key opinion leader J. David Farrar, PhD, Associate Professor, Immunology/Molecular Biology, UT Southwestern Medical Center.

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

WARREN, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced it will hold a virtual investor day on September 27, 2024 at 8:00 am ET to discuss the Company's pipeline updates, inclusive of Anaphylm™ (epinephrine) Sublingual Film and AQST-108 (epinephrine) Topical Gel, both candidate products emerging from the Company's Adrenaverse™ epinephrine prodrug platform. The event will include presentations by members of the Aquestive management team and by a distinguished key opinion leader J. David Farrar, PhD, Associate Professor, Immunology/Molecular Biology, UT Southwestern Medical Center.

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

Aquestive Therapeutics Q2 earnings report showed significant beats in EPS and revenue, with a 52% year-over-year revenue increase. The company reported improved operational efficiency and profitability, with a positive non-GAAP adjusted EBITDA of $1.8M and $89.9M in cash, extending their cash runway into 2026. Aquestive provided updates on Anaphylm's progress towards an NDA submission in early 2025, as well as advancements in their Adrenaverse platform and Libervant's market access.

Aquestive Therapeutics: Bullish Roadmap After Q2 Earnings

WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in two upcoming investor conferences in September 2024 as follows:

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

Aquestive Therapeutics shares surged 137.29% (YoY) after FDA approval of rival company ARS Pharmaceutical's "epinephrine nasal spray" Neffy. Market optimism surrounds AQST's robust R&D pipeline, with analysts giving outperform rating and price target increase to $15. AQST recorded significant revenue growth in Q2 2024, with a cash balance of $89.87 million and sufficient funds until the end of 2026.

Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025

Aquestive Therapeutics Inc. (NASDAQ:AQST ) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Bennett Watson - ICR Westwicke Investor Relations Dan Barber - Chief Executive Officer Ernie Toth - Chief Financial Officer Carl Kraus - Chief Medical Officer Stephen Wargacki - Chief Science Officer Sherry Korczynski - Senior Vice President of Sales and Marketing Conference Call Participants Roanna Ruiz - Leerink Partners David Amsellem - Piper Sandler François Brisebois - Oppenheimer Raghuram Selvaraju - H.C. Wainwright Thomas Flaten - Lake Street Securities Jason Butler - Citizens JMP Gary Nachman - Raymond James James Molloy - Alliance Global Partners Operator Good morning, and welcome to the Aquestive Therapeutics Second Quarter 2024 Conference Call.

Aquestive Therapeutics Inc. (AQST) Q2 2024 Earnings Call Transcript

Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.10 per share a year ago.

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

WARREN, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, reported financial results for the second quarter, which ended June 30, 2024, and provided an update on recent developments in its business.

Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

WARREN, N.J., July 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today released positive topline PK data from the self-administration study of Anaphylm™ (epinephrine) Sublingual Film. Anaphylm has the potential to be the first and only non-invasive, orally delivered epinephrine for the treatment of severe life-threatening allergic reactions, including anaphylaxis, if approved by the United States Food and Drug Administration (FDA).

Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study

WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the second quarter ended June 30, 2024 and provide an update on recent developments in its business after market close on Tuesday, August 6, 2024.

Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET

American Airlines

Albemarle

ALB, AAL and AQST have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2024.

New Strong Sell Stocks for July 16th

Central Garden & Pet Company

LiveRamp Holdings Inc

AQST, CENTA and RAMP have been added to the Zacks Rank #5 (Strong Sell) List on July 11, 2024.

New Strong Sell Stocks for July 11th

WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host investor meetings on July 9, 2024. The forum will include panels exploring key therapeutic themes across the fields of immunology and inflammation (I&I) and metabolism.

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

WARREN, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced it has strengthened its leadership team with three executive appointments ahead of the anticipated launch of Anaphylm™ (epinephrine) Sublingual Film, the Company's epinephrine prodrug product candidate that has the potential to be the first and only non-invasive, orally delivered epinephrine for the treatment of severe life-threatening allergic reactions, including anaphylaxis, if approved by the U.S. Food and Drug Administration (FDA). Sherry Korczynski joined the Aquestive leadership team as Senior Vice President, Sales and Marketing. Cassie Jung was promoted to Chief Operating Officer, and Stephen Wargacki, Ph.D., was named Chief Science Officer.

Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities

Acrivon Therapeutics Inc

Bioventus

Cardiol Therapeutics

Heron Therapeutics

Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy From a Recovering Industry

WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in The Citizens JMP Life Sciences Conference on May 13, 2024.

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference

Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Bennett Watson – ICR Westwicke Investor Relations Dan Barber – Chief Executive Officer and President Ernie Toth – Chief Financial Officer Stephen Wargacki – Chief Science Officer Conference Call Participants David Amsellem – Piper Sandler Francois Brisebois – Oppenheimer Ram Selvaraju – H.C. Wainwright Gary Nachman – Raymond James Thomas Flaten – Lake Street Capital Markets Operator Good morning, and welcome to Aquestive Therapeutics First Quarter 2024 Conference Call.

Aquestive Therapeutics, Inc. (AQST) Q1 2024 Earnings Call Transcript

The headline numbers for Aquestive Therapeutics (AQST) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

News for Aquestive Therapeutics Inc Stock (AQST)